Professor Anton Middelberg
|Professor Anton Middelberg, above, and PhD student Alemu Tekewe Mogus explains his research, below.|
Research: Biomolecular engineering
Professor Middelberg and his team conduct research in vaccine engineering, biosurfactants and bio-inspired nanomaterials. Projects encompass new technologies for cost-effective rapid vaccine development, sustainable biosurfactant technologies and nanomedicine approaches based on fundamental understanding of bio-nano interactions. Research teams collaborate extensively nationally and internationally, with regular invitations to global events. Recent funding from the Bill & Melinda Gates Foundation is targeting low-cost vaccine solutions to Rotavirus for the developing world. Alemu Tekewe Mogus joined the group from Ethiopia to advance the project. His journey is captured in a recent video.
Professor Middelberg is Editor-in-Chief of leading international journal Chemical Engineering Science. He is Associate Editor of Vaccine and an Editorial Advisory Board Member for Trends in Biotechnology. Professor Middelberg has editorial roles on the Biochemical Engineering Journal, the Journal of Microbiology and Biotechnology and Pharmaceutical Bioprocessing. He has joint publications with researchers from Tianjin University, China; Oxford and Cambridge Universities, UK; University of California Berkeley, US; KAIST, Korea; and a number of companies including Eli Lilly, Novartis and Dow. Professor Middelberg has served in scientific roles for numerous international conferences including the International Biotechnology Symposium (Daegu, South Korea, 2012); the International Small-Angle Scattering Conference (Sydney, 2012); the Asian Congress of Biotechnology (Shanghai, China, 2011); and Recovery XIV (Lake Tahoe, USA, 2010).
Memberships, patents and funding
Professor Middelberg is an elected a Fellow of the Australian Academy of Technological Sciences and Engineering and a Fellow of the Institution of Chemical Engineers UK. Professor Middelberg has attracted more than $13 million in research funding since 2003 and has been named as an inventor on almost 58 patents and applications.
Awards and plenaries
Professor Middelberg’s invention of peptide surfactants was awarded three major prizes including the 2006 TechConnect Prize in Boston. His recent invitations include plenary lectures at the World Congress of Particle Technology in Beijing (2014); the World Congress of Chemical Engineering 9 GLS-11 in Seoul (2013); the 7th Vaccines and ISV Conference in Barcelona (2013); and the 14th Asia Pacific Confederation of Chemical Engineering Congress in Singapore (2012). He annually attends either the AIChE or ECCE meeting where, in his capacity as Editor-in-Chief of Chemical Engineering Science, he introduces the Danckwerts Award Lecturer.
Key publications for the past five years
Dimitrijev Dwyer M, Brech M, Yu AL, Middelberg APJ. (2014) Intensified expression and purification of a recombinant biosurfactant protein. Chem Eng Sci 105, 12-21.
Zeng BJ, Chuan YP, O’Sullivan B, Caminschi I, Lahoud MH, Thomas R, Middelberg APJ. (2013) Receptor-specific delivery of protein antigen to dendritic cells by a nanoemulsion formed using top-down non-covalent click self-assembly. Small 9(22), 3736-3742 (frontispiece).
Wibowo N, Chuan YP, Lua LHL, Middelberg APJ. (2013) Modular engineering of a microbially-produced viral capsomere vaccine for influenza. Chem Eng Sci 103, 12-20.
Chuan YP, Rivera-Hernandez T, Wibowo N, Connors NK, Wu Y, Hughes FK, Lua LHL, Middelberg APJ. (2013) Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine. Biotechnol Bioeng 110(9), 2343-2351 (front cover).
Middelberg APJ, Rivera-Hernandez T, Wibowo N, Lua LHL, Fan YY, Magor G, Chang C, Chuan YP, Good MF, Batzloff MR. (2011) A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine 29(41), 7154-7162.
|Professor Anton Middelberg section|